eClinical Tech News

Assembly Biosciences presented data at the 2025 ESCMID Congress on ABI-5366, a novel, long-acting helicase-primase inhibitor candidate for recurrent...

Annexon, Inc. presented Phase 3 trial data for tanruprubart (formerly ANX005), a C1q-blocking monoclonal antibody, at the 2025 AAN...

Cerevance announced positive Phase 1 trial results for CVN293, a novel KCNK13 inhibitor targeting neuroinflammation. The drug was well-tolerated...

Recursion Pharmaceuticals has dosed the first patient in a Phase 1 clinical trial, EXCELERIZE, for REC-3565, a potential best-in-class...

NKGen Biotech announced updated Phase 1 clinical trial data for troculeucel, an NK cell therapy for moderate Alzheimer’s disease....

TG Therapeutics announced the publication of two articles, one examining the evolution of CD20 treatments for multiple sclerosis (MS)...

Rhythm Pharmaceuticals announced positive topline results from its Phase 3 TRANSCEND trial of setmelanotide for acquired hypothalamic obesity. The...

iBio announced promising preclinical data for IBIO-600, a long-acting anti-myostatin antibody, and a first-in-class Activin E antibody, both targeting...

Tr1X, a clinical-stage biopharmaceutical company, received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to...

Sonnet BioTherapeutics announced positive safety results for SON-1010, an IL-12 based immunotherapy, combined with atezolizumab in a Phase 1b/2a...